liraglutide / Generic mfg. - LARVOL DELTA

Duodenal Neuroendocrine Tumor Revealed by Escherichia coli Bacteremia: Possible Implication of Tirzepatide (ACG 2026) - "Case Description/ A 62-year-old female with known history of hypertension, hyperlipidemia and obesity, for which she was initially on liraglutide then switched to tirzepatide two months prior to admission...The Patient was diagnosed with sepsis and started immediately on piperacillin tazobactam...The patient received pantoprazole 40 mg twice daily and sucralfate, resulting in improvement of abdominal pain...In our patient, the ulcer likely contributed actively to the translocation, especially in the neoplastic conditions. Figure: Duodenal Bulbar Ulcer With Pigmented Material"

Cardiovascular • Dyslipidemia • Endocrine Cancer • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Hypertension • Immunology • Infectious Disease • Neuroendocrine Tumor • Obesity • Oncology • Peptic Ulcer • Septic Shock • Solid Tumor

Trends in Endoscopic Sleeve Gastroplasty Utilisation Among Patients With Obesity, Overweight, and Diabetes: A Multi-Institutional Retrospective Analysis Over 5 Years (ACG 2026) - "GLP-1 RA use post ESG was dominated by semaglutide (8%), liraglutide (4%), dulaglutide (4%) and tirzepatide (2%) as in table 2... A total of 5,201 patients with DM, Obesity and overweight underwent ESG which was predominantly utilized by middle-aged White, non-Hispanic females with mean age around 56 years. ESG recipients demonstrated a substantial burden of cardiometabolic disease, including diabetes, hypertension, ischemic heart disease and also GERD and Gastritis. Baseline characteristics and other associated comorbidities are described in table 1."

Retrospective data • Cardiovascular • Coronary Artery Disease • Diabetes • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Hypertension • Metabolic Disorders • Obesity

GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application. (PubMed, Int J Mol Sci) - "Randomized pediatric trials demonstrate clinically meaningful BMI reduction with liraglutide and semaglutide, with the largest mean effect reported for semaglutide in adolescents; however, long-term effects on growth, puberty, bone health, body composition, and weight maintenance remain uncertain...Incretin-based therapies should be integrated with nutritional, behavioral, psychological, and family-based care. Their future value will depend on durable efficacy, developmental safety, equitable access, and identification of patients most likely to benefit."

Journal • Review • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Pediatrics

Comparative Effectiveness of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Metabolic DysfunctionâAssociated Steatotic Liver Disease: A Systematic Review and Meta-Analysis (ACG 2026) - "Fourteen studies comprising approximately 3,200 patients were included. GLP-1 receptor agonists, primarily semaglutide and liraglutide, were associated with greater reductions in liver fat content compared with SGLT2 inhibitors (mean difference â5.8% vs â3.1%), as well as greater weight loss (â8.5% vs â3.2%) and larger reductions in ALT (â18 U/L vs â11 U/L). SGLT2 inhibitors evaluated included empagliflozin and dapagliflozin."

HEOR • Retrospective data • Review • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

Real-World Discontinuation of GLP-1âBased Therapies for Obesity: A Systematic Review and Meta-Analysis (ACG 2026) - "Thirty-eight studies (N=307,190 patients) were included. At 6 months, the pooled discontinuation incidence for all agents was 47% (95% CI 38-57%). Discontinuation differed by agent: liraglutide 52%, semaglutide 46%, and tirzepatide 35% (p=0.04; Figure 1)."

Real-world • Real-world evidence • Retrospective data • Review • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Association Between GLP-1 Receptor Agonist Exposure and Acute Pancreatitis Risk in Patients With Cholelithiasis: A Real-World Cohort Study (ACG 2026) - "Introduction: GLP-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes and obesity...Adults (â¥18 years) with cholelithiasis who were exposed to GLP-1 RAs (semaglutide, dulaglutide, liraglutide, exenatide, tirzepatide) were compared to unexposed patients... 162,458 patients were included per cohort. For the primary outcome, 152,331 vs 151,712 patients were compared, and acute pancreatitis occurred in 2,172 (1.43%) vs 2,979 (1.96%) (RD -0.54%, 95% CI -0.63 to -0.45%; RR 0.73, 95% CI 0.69-0.76; HR 0.64, 95% CI 0.61-0.68; p< 0.001). 158,091 vs 158,395 patients were compared for the secondary outcome and gallstone pancreatitis occurred in 998 (0.63%) vs 1,745 (1.102%) (RD -0.47%, 95% CI -0.54 to -0.41%; RR 0.57, 95% CI 0.53-0.62; p< 0.001) (Table 1)."

Clinical • Real-world • Real-world evidence • Diabetes • Gastroenterology • Genetic Disorders • Metabolic Disorders • Obesity • Pancreatitis • Type 2 Diabetes Mellitus

Comparative Efficacy of Endoscopic Sleeve Gastroplasty and Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss: Systematic Review and Meta-Analysis (ACG 2026) - "Three studies (1 RCT and 2 retrospective cohorts) were included. Semaglutide was used in two of the studies, while liraglutide and tirzepatide were used in one study each. The ESG group comprised 265 patients (mean age 45.5; 29.8% males), while the GLP1RA group included 141 patients (mean age 52.6; 27.7% male)."

Retrospective data • Review • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Colorectal Cancer Among Adults With Obesity: A Multicenter Real-World Cohort Study (ACG 2026) - "After matching,1,340,395 adults remained in each cohort achieving demographic balance(mean age 52 years; 66% female; 69% White,19% Black & 2% Asian).GLP-1RA exposure was associated with a 67.5% lower risk of composite CRC with significant reductions in CC(RR 0.495,95% CI 0.479â0.512) and RC(0.411,0.386â0.437).Associations remained significant in adults< 45 years with particularly pronounced reduction in RC(0.289, 0.214â0.389) & CC(0.428, 0.358â0.512).Findings were consistent across BMI strata and among individuals with concomitant obesity and diabetes.Drug-specific analyses with semaglutide,tirzepatide & dulaglutide demonstrated significant reductions in both CC and RC risk.Liraglutide was associated with lower RC risk, whereas no significant associations were observed with exenatide. Myopia, used as a negative control outcome demonstrated a near-null association In this large real-world cohort of adults with obesity, GLP-1RA use was..."

Clinical • Real-world • Real-world evidence • Colon Cancer • Colorectal Cancer • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Oncology • Ophthalmology • Solid Tumor

Glucagon-Like Peptide-1 Receptor Agonists Affect the Progression of Barrett's Esophagus (ACG 2026) - "Short acting GLP-1RA are exenatide, lixisenatide and liraglutide, whereas long acting GLP-1RA are semaglutide and dulaglutide. After PSM, 2,473 patients were identified in each of the groups in the short-acting GLP-1RA analysis, and 21,406 patients were identified in the each of the groups in the long-acting GLP-1RA analysis. In the short-acting analysis, the incidence of progression to dysplasia over the 10-year follow-up was 8.1% (187/2,316) in users compared with 5.9% (135/2,302) in controls (RR, 1.37; 95% CI, 1.11â1.70; P = 0.003). The incidence of EAC in this analysis was too low to be reported."

Barrett Esophagus • Esophageal Adenocarcinoma • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Obesity • Solid Tumor

Economic evaluations of antiobesity medications: A systematic literature review. (PubMed, Br J Clin Pharmacol) - "We systematically reviewed full economic evaluations of approved antiobesity medications in adults with overweight or obesity, including tirzepatide, semaglutide, liraglutide, naltrexone/bupropion, orlistat, phentermine and phentermine/topiramate. Direct comparative economic evidence between newer agents remains limited. Long-term real-world data and clearer distinctions between cost-effectiveness and affordability are needed to inform policy decisions."

HEOR • Journal • Review • Genetic Disorders • Obesity

Rapid Growth in Medicare Part D Spending on GLP-1 Receptor Agonists Prescribed by Gastroenterologists, 2017â2023 (ACG 2026) - " Using the CMS Medicare Part D Prescriber by Provider and Drug dataset (2017â2023), we extracted all GLP-1 RA claims (dulaglutide, exenatide formulations, liraglutide, semaglutide, tirzepatide) attributed to gastroenterology providers...Because Medicare Part D excludes coverage for anti-obesity medications, observed prescribing likely reflects diabetes- and cardiovascular-related indications and may underestimate future GI demand related to obesity and MASLD management... Medicare Part D spending on GI-prescribed GLP-1 RAs rose 22-fold, from $571,569 in 2017 to $12,665,583 in 2023; 30-day fills grew 14.7-fold (876 to 12,862). Semaglutide accounted for most spending growth, increasing from $126,162 (169 fills) in 2019 to $8,798,765 (9,098 fills) in 2023 and comprising 69% of 2023 GLP-1 spending. Tirzepatide grew from $70,856 in 2022 to $1,942,314 in 2023."

Medicare • Reimbursement • US reimbursement • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

Tirzepatide Shows No Serious GI Disproportionality vs Semaglutideâs 4.55Ã Intestinal Obstruction Signal: An OpenFDA FAERS Pharmacovigilance Study of GLP-1 Receptor Agonists, 2018â2025 (ACG 2026) - " We queried OpenFDA FAERS (Jan 2018-May 2025) for injectable semaglutide (n=48,509), oral semaglutide (5,421), tirzepatide (79,699), liraglutide (17,381), dulaglutide (68,858), and metformin as a non-GLP-1 comparator (214,667; total 434,535 reports)... Injectable semaglutide showed the strongest serious-GI disproportionality: intestinal obstruction ROR 4.55 (4.10-5.05, n=558), ileus 4.98 (4.23-5.86), cholecystitis 3.18 (2.68-3.79), constipation 2.62, vomiting 2.15, and nausea 2.05-all confirmed signals. Tirzepatide, despite 79,699 reports, showed no serious-GI signal: intestinal obstruction ROR 0.83 (0.73-0.95), ileus 0.87 (0.70-1.08), cholecystitis 0.79 (0.63-0.98), and pancreatitis 0.33 (0.27-0.40)-all below unity. Oral semaglutide had significantly lower intestinal-obstruction disproportionality than injectable head-to-head (ROR 0.72 [0.53-0.98], p=0.025)."

Adverse events • Constipation • Gastroenterology • Gastrointestinal Disorder • Hepatology • Pancreatitis

GLP-1 Receptor Agonist Use Is Associated With Increased Esophageal Acid Exposure: A Matched Case Control Study (ACG 2026) - "Introduction: Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well known to promote significant weight loss, they have also been associated with gastrointestinal symptoms, including nausea, vomiting, constipation, and gastroesophageal reflux...Among those on GLP-1 RAs, 14 were taking semaglutide,13 liraglutide, 10 exenatide, 10 tirzepatide, and 2 dulaglutide... Forty-nine patients using GLP-1 RAs who underwent 48-hour ambulatory pH monitoring were included and matched to 147 control patients. There were no significant differences in sex, age, or BMI between the two groups (Table 1). Type 2 diabetes was more common among patients than controls (65% vs."

Clinical • Addiction (Opioid and Alcohol) • Constipation • Diabetes • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Metabolic Disorders • Type 2 Diabetes Mellitus

Concurrent Thiazolidinediones and GLP-1 Receptor Agonists Therapy in MASH Cirrhosis Patients: A Propensity-Score-Matched Retrospective Cohort Study (ACG 2026) - "Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis carries a significant clinical burden with unmet therapeutic needs... Our retrospective cohort study utilized the TriNetX US Collaborative Network to identify patients with MASH-related cirrhosis (ICD-10: K75.81/K76.0 plus K74.6/K74.69) receiving GLP-1RA/GIP (semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, or albiglutide) alone or with TZD (pioglitazone or rosiglitazone)... After matching, cohorts were well balanced (mean age 58.5 years; 81% White; 78% T2DM; 10% esophageal varices) except for higher BMI and HbA1c in combination cohort, reflecting TZD use as add-on therapy for refractory hyperglycemia. The combination group demonstrated a 37% relative reduction in all-cause mortality (3.7% vs. 5.1%; risk difference â1.4%, 95% CI â2.4% to â0.4%; p=0.007; HR 0.63, 95% CI 0.50â0.80; log-rank p0.001)."

Retrospective data • CNS Disorders • Diabetes • Fibrosis • Gastroenterology • Hematological Disorders • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Immunology • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Nephrology • Renal Disease • Solid Tumor • Type 2 Diabetes Mellitus

Clinical Outcomes of GLP-1 Receptor Agonist Use in Patients With Pre-Existing Gastroparesis With Type 2 Diabetes and/or Obesity (ACG 2026) - "Adults (â¥18 years) with confirmed gastroparesis (ICD-10 K31.84) and type 2 diabetes and/or obesity prior to GLP-1 initiation were stratified into GLP-1 users (semaglutide, tirzepatide, liraglutide, dulaglutide, lixisenatide, exenatide) vs. non-users... Of 138,793 eligible gastroparesis patients, 1,800 received GLP-1 agonists. After 1:1 PSM (n=1,792/cohort), GLP-1 use was associated with lower 1-year mortality (3% vs. 5.7%, RR 0.53, 95% CI 0.38-0.73, p< 0.001), SBO/ileus (1.3% vs."

Clinical • Clinical data • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Infectious Disease • Metabolic Disorders • Obesity • Pneumonia • Respiratory Diseases • Type 2 Diabetes Mellitus

Efficacy and Safety of Incretin-Based Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Trials (ACG 2026) - "Agents included liraglutide, semaglutide, dulaglutide, tirzepatide, pemvidutide, survodutide, efinopegdutide, and retatrutide... Sixteen MASLD/MASH randomized trials were included. Five biopsy-based trials contributed to MASH/NASH resolution without worsening fibrosis (n=1,226); incretin-based therapy increased resolution versus control (RR 2.80, 95% CI 1.60â4.90; p=0.007; I²=66.6%). Four biopsy-based trials reported fibrosis improvement without MASH worsening (n=1,181), favoring incretin-based therapy (RR 1.52, 95% CI 1.13â2.05; p=0.021; I²=0%)."

Retrospective data • Review • Constipation • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

GLP-1 and GIP Receptor Agonists Are Safe in Ulcerative Colitis Patients With an Ileal Pouch-Anal Anastomosis: A Retrospective Case Series (ACG 2026) - "Six patients (5 women; median age 63 years, range 47â77) were treated with tirzepatide (n=4), semaglutide (n=1), or liraglutide (n=1). Four underwent follow-up pouchoscopy; median time to endoscopy after GLP1 initiation was 36 months (IQR 32â42). BMI decreased from 37.6 to 35.2 kg/m² (median â3.6; p=0.031) and HbA1c from 7.0 to 5.9% (median â0.7%; p=0.031)."

Retrospective data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Can GLP-1 Therapy Prevent Post-Bariatric Alcohol Use Disorder? A Propensity-Matched Multicenter Cohort Study (ACG 2026) - "Adults with prior RYGB were identified and categorized according to subsequent exposure to GLP-1RAs (semaglutide, tirzepatide, liraglutide, dulaglutide, or exenatide). Patients with liver transplantation or pregnancy were excluded... After propensity score matching, 8,463 patients were included in each cohort. GLP-1RA therapy was associated with a significantly lower risk of developing incident alcohol-related disease compared with no GLP-1RA exposure (1.4% vs 2.4%; RR 0.56, 95% CI 0.45â0.71; p< 0.001). Patients receiving GLP-1RAs also had a lower incidence of alcohol abuse (0.8% vs 1.6%; RR 0.53, 95% CI 0.40â0.71; p< 0.001)."

Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Genetic Disorders • Hepatology • Inflammation • Liver Failure • Mental Retardation • Metabolic Disorders • Obesity • Tobacco Addiction

GLP-1 Receptor Agonists and Tirzepatide in Men Seeking Fertility: A Structured Narrative Review and Proposed Clinical Framework. (PubMed, J Clin Med) - "Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide are increasingly used to treat obesity and type 2 diabetes in men of reproductive age, but practical guidance for counseling men planning fatherhood remains limited...In metabolically impaired men, studies largely involving liraglutide or semaglutide report increases in total testosterone; free-testosterone findings are inconsistent, and the available small short-term studies did not show the marked gonadotropin suppression expected with exogenous testosterone...These therapies should be used for established metabolic indications, not as male infertility treatments. The proposed framework is author-developed, evidence-informed, non-validated, and intended for individualized counseling and prospective evaluation."

Journal • Review • Diabetes • Endocrine Disorders • Genetic Disorders • Infertility • Metabolic Disorders • Obesity • Sexual Disorders • Type 2 Diabetes Mellitus

Post-Colonoscopy GLP-1 Receptor Agonist Use and Subsequent Bowel Preparation Outcomes: A Propensity-Matched Real-World Cohort Study (ACG 2026) - "Cohort 1 initiated a GLP-1RA (semaglutide, tirzepatide, liraglutide, dulaglutide, or lixisenatide) following index colonoscopy... After matching, cohorts were well balanced (66.7% female, 56.7% White). GLP-1RA use was associated with significantly lower rates of inadequate bowel preparation (3.8% vs 8.4%; RR 0.44, 95% CI 0.41â0.48; p< 0.001), need for additional bowel regimen (9.3% vs 13.2%; RR 0.71; p< 0.001), and repeat colonoscopy (7.6% vs 13.0%; RR 0.58, 95% CI 0.55â0.61; p< 0.001). Colonoscopy-related complications were also less frequent (0.21% vs 0.58%; RR 0.36; p< 0.001)."

Clinical • Real-world • Real-world evidence • Colorectal Cancer • Gastrointestinal Disorder • Inflammatory Bowel Disease

GLP-1 receptor agonists and ocular safety- Pharmacokinetic insights into ischemic optic neuropathy and diabetic retinopathy risk: A review. (PubMed, Biomol Biomed) - "Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of type 2 diabetes mellitus and obesity, but their expanding use has raised concerns about ocular safety...The most consistent NAION signal involved high-exposure subcutaneous semaglutide, whereas findings for oral semaglutide, liraglutide, dulaglutide, exenatide, and tirzepatide were absent, inconsistent, or weaker...Semaglutide 7.2 mg, with an estimated Css of approximately 230 nmol/L, and highly bioavailable oral orforglipron warrant formulation-specific postmarketing ocular surveillance, although direct evidence of NAION risk remains unavailable. Current evidence does not support class-wide prescribing restrictions. An individualized approach considering patient-specific ocular risk, agent, formulation, and dose is more appropriate, while prospective studies with standardized ophthalmic endpoints are needed to establish causality and validate pharmacokinetic and pharmacogenomic..."

Journal • PK/PD data • Review • Diabetes • Diabetic Neuropathy • Diabetic Retinopathy • Genetic Disorders • Metabolic Disorders • Obesity • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Retinal Disorders • Type 2 Diabetes Mellitus

GLP-1 Receptor Agonists and Respiratory Outcomes in Achalasia: A Real-World Propensity-Matched Cohort Study (ACG 2026) - "Adults with achalasia (ICD-10 K22.0) who received GLP-1RAs (liraglutide, semaglutide, dulaglutide, exenatide, or lixisenatide) were compared with achalasia patients without GLP-1RA exposure. Among 68,630 patients with achalasia, 1,700 received GLP-1RAs. After propensity score matching, 1,695 patients remained in each cohort. GLP-1RA use was associated with a significantly lower risk of aspiration pneumonia compared with non-use (1.0% vs 4.8%; RR 0.21, 95% CI 0.12â0.35; HR 0.22, 95% CI 0.13â0.37; p< 0.001)."

Clinical • Real-world • Real-world evidence • Amyotrophic Lateral Sclerosis • Cardiovascular • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • CNS Disorders • Diabetes • Dyslipidemia • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Movement Disorders • Nephrology • Obesity • Obstructive Sleep Apnea • Parkinson's Disease • Pneumonia • Pulmonary Disease • Rare Diseases • Renal Disease • Respiratory Diseases • Sleep Disorder

GLP-1 Receptor Agonists and Metachronous Adenoma Recurrence After Colonoscopic Polypectomy: A Propensity-Matched Real-World Analysis of 12,152 Patients (ACG 2026) - "Exposed patients initiated GLP-1 RA (tirzepatide, liraglutide, dulaglutide, exenatide, semaglutide) 1-180 days post-polypectomy; unexposed never received one. 1:1 propensity matching used 22 covariates, including age, sex, race, ethnicity, diabetes, obesity, hypertension, hyperlipidemia, tobacco, alcohol, family history of GI cancer, IBD, aspirin, metformin, BMI, and HbA1c... 6,076 matched pairs were analyzed; 21 of 22 covariates achieved SMD< 0.10. The mean follow-up was 1,411 vs 1,507 days. Metachronous adenoma occurred in 31.1% exposed vs 36.5% unexposed (HR 0.82, 0.77-0.87; p< 0.0001)."

Clinical • Real-world • Real-world evidence • Colorectal Cancer • Diabetes • Dyslipidemia • Gastrointestinal Cancer • Genetic Disorders • Hypertension • Metabolic Disorders • Obesity • Skin Cancer • Solid Tumor

GLP-1/GIP Receptor Agonists and Liver-Related Outcomes in Metabolic Dysfunction-Associated Steatohepatitis With Hepatic Fibrosis: A Propensity-Matched Real-World Analysis (ACG 2026) - "GLP-1/GIP users (semaglutide, tirzepatide, or liraglutide) were propensity score matched 1:1 to non-users on age, sex, BMI, comorbidity burden, and baseline liver disease severity, yielding balanced cohorts of 7,634 patients each... GLP-1/GIP therapy was associated with markedly lower all-cause mortality (3.0% vs 9.3%; HR 0.39, p< 0.001), chronic liver failure (HR 0.43, p< 0.001), and acute liver failure (HR 0.43, p< 0.001). Cirrhosis incidence was halved (HR 0.53, p< 0.001). Portal hypertension (HR 0.59, p=0.005) and ascites (HR 0.59, p=0.016) were substantially reduced."

Clinical • Real-world • Real-world evidence • Cardiovascular • Diabetes • Fibrosis • Genetic Disorders • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Pancreatitis • Portal Hypertension • Type 2 Diabetes Mellitus

GLP-1 Agonist Use and Outcomes in Connective Tissue Disease-Associated Interstitial Lung Disease (ACR Convergence 2026) - "Patients were categorized as GLP-1 RA users (including semaglutide, dulaglutide, liraglutide, albiglutide, exenatide, lixisenatide) or non-users, and outcomes were evaluated over a 5-year follow-up. In this large propensity score-matched cohort of patients with CTD-ILD, GLP-1 RA use was associated with a significantly reduced risk of mortality. These findings suggest a potential protective role of GLP-1-based therapies and support prospective studies to further define their role in risk modification and disease outcomes in CTD-ILD."

Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Genetic Disorders • Heart Failure • Inflammatory Arthritis • Interstitial Lung Disease • Metabolic Disorders • Myocardial Infarction • Myositis • Obesity • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Scleroderma • Sjogren's Syndrome • Systemic Sclerosis • Type 2 Diabetes Mellitus